Authors

  • Таштемиров Ф.Р., Юнусова З.Д., Абдурахманова Н.Р., Латипова Н.Р., Кодирова И.Т., Марданов А.К., Аброров Ш.З., Оразханов Д.О.

Keywords:

Острый миелоидный лейкоз, венетоклакс, азацитидин, длительность терапии.

References

Cancer Facts & Figures 2018. American Cancer Society. 2018, Dӧhner et al., N Engl J Med. 2015; 373: p1136

DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with azacitidine or decitabine in treatment-naive, elderly patients with acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971

Jing Lu, Sheng-li Xue, Ying Wang, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood (2025) 145 (22): 2645–2655. doi.org/10.1182/blood.2024027217

Kanaya, M., Onozawa, M., Matsukawa, T. et al. Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J. 15, 118 (2025). doi.org/10.1038/ s41408-025-01324-7

Jitesh D. Kawedia, Caitlin R. Rausch et al. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. American Journal of Hematology. Volume100, Issue 4. April 2025. Pages 740-743. doi.org/10.1002/ ajh.27613

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood (2022) 140 (12): 1345–1377. doi.org/10.1182/ blood.2022016867